Literature DB >> 8673695

Vaccine therapy for malignant melanoma.

D L Morton1, A Barth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8673695     DOI： 10.3322/canjclin.46.4.225

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


× No keyword cloud information.
  16 in total

1.  Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.

Authors:  Lei Qiu; Xi Gong; Qianli Wang; Jie Li; Honggang Hu; Qiuye Wu; Junping Zhang; Zhongwu Guo
Journal:  Cancer Immunol Immunother       Date:  2012-04-27       Impact factor: 6.968

Review 2.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

3.  Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Authors:  Huafeng Wei; Pu Liu; Elizabeth Swisher; Yuen Yee Yip; Jee Hang Tse; Kathy Agnew; Karl Erik Hellström; Ingegerd Hellström
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

Review 4.  Targeted therapy for malignant melanoma.

Authors:  C K Brown; J M Kirkwood
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

5.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

6.  Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.

Authors:  Mark B Faries; Eddy C Hsueh; Xing Ye; Mary Hoban; Donald L Morton
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

7.  Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell.

Authors:  Qianli Wang; Junping Zhang; Zhongwu Guo
Journal:  Bioorg Med Chem       Date:  2007-09-12       Impact factor: 3.641

8.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

Review 9.  Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches.

Authors:  Jose L Daniotti; Aldo A Vilcaes; Vanina Torres Demichelis; Fernando M Ruggiero; Macarena Rodriguez-Walker
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

10.  A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.

Authors:  Lei Qiu; Jie Li; Shichong Yu; Qianli Wang; Yinghua Li; Zhenlin Hu; Qiuye Wu; Zhongwu Guo; Junping Zhang
Journal:  Oncotarget       Date:  2015-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.